The Medicines Company Files Patent Infringement Lawsuits

PARSIPPANY, NJ, Oct 08 (MARKET WIRE) --
The Medicines Company (NASDAQ: MDCO) today announced that it has filed
lawsuits against Teva Parenteral Medicines, Inc., Pliva Hrvatska d.o.o.
and APP Pharmaceuticals, LLC, and related entities in the United States
District Court for the District of Delaware alleging patent infringement
based on Abbreviated New Drug Applications seeking U.S. Food and Drug
Administration approval to market and sell generic versions of The
Medicines Company's Angiomax(R) product prior to expiration of U.S.
Patent No. 7,582,727 ("the '727 patent").

Each lawsuit alleges infringement of the '727 patent. As previously
announced, the '727 patent was issued to The Medicines Company on
September 1, 2009.

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) is focused on advancing the treatment
of critical care patients through the delivery of innovative,
cost-effective medicines to the worldwide hospital marketplace. The
Company markets Angiomax(R) (bivalirudin) in the United States and other
countries for use in patients undergoing coronary angioplasty, and
Cleviprex(R) (clevidipine butyrate) injectable emulsion in the United
States for the reduction of blood pressure when oral therapy is not
feasible or not desirable. The Company's website is
www.themedicinescompany.com.

Statements contained in this press release about The Medicines Company
that are not purely historical, and all other statements that are not
purely historical, may be deemed to be forward-looking statements for
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Without limiting the foregoing, the words
"believes," "anticipates" and "expects" and similar expressions, including
the Company's preliminary revenue results, are intended to identify
forward-looking statements. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the Company's actual
results, levels of activity, performance or achievements to be materially
different from those expressed or implied by these forward-looking
statements. Important factors that may cause or contribute to such
differences include the extent of the commercial success of Angiomax, the
Company's ability to develop its global operations and penetrate foreign
markets, whether the Company's products will advance in the clinical
trials process on a timely basis or at all, whether the Company will make
regulatory submissions for product candidates on a timely basis, whether
its regulatory submissions will receive approvals from regulatory agencies
on a timely basis or at all, whether physicians, patients and other key
decision makers will accept clinical trial results, risks associated with
the establishment of international operations, and such other factors as
are set forth in the risk factors detailed from time to time in the
Company's periodic reports and registration statements filed with the
Securities and Exchange Commission including, without limitation, the risk
factors detailed in the Company's Quarterly Report on Form 10-Q filed on
August 10, 2009, which are incorporated herein by reference. The Company
specifically disclaims any obligation to update these forward-looking
statements.

Contact:
Robyn Brown
Vice President, Investor Relations
The Medicines Company
973-290-6000
investor.relations@themedco.com

Copyright 2009, Market Wire, All rights reserved.

-0-